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Abstract
Background: Inadequate surgical hemostasis may lead to transfusion and/or other bleeding-related complications.
This study examines the incidence and costs of bleeding-related complications and/or blood product transfusions
occurring as a consequence of surgery in various inpatient surgical cohorts.
Methods: A retrospective analysis was conducted using Premier’s Perspective™ hospital database. Patients who
had an inpatient procedure within a specialty of interest (cardiac, vascular, non-cardiac thoracic, solid organ,
general, reproductive organ, knee/hip replacement, or spinal surgery) during 2006-2007 were identified. For each
specialty, the rate of bleeding-related complications (including bleeding event, intervention to control for bleeding,
and blood product transfusions) was examined, and hospital costs and length of stay (LOS) were compared
between surgeries with and without bleeding-related complications. Incremental costs and ratios of average total
hospital costs for patients with bleeding-related complications vs. those without complications were estimated
using ordinary least squares (OLS) regression, adjusting for demographics, hospital characteristics, and other
baseline characteristics. Models using generalized estimating equations (GEE) were also used to measure the
impact of bleeding-related complications on costs while accounting for the effects related to the clustering of
patients receiving care from the same hospitals.
Results: A total of 103,829 cardiac, 216,199 vascular, 142,562 non-cardiac thoracic, 45,687 solid organ, 362,512
general, 384,132 reproductive organ, 246,815 knee/hip replacement, and 107,187 spinal surgeries were identified.
Overall, the rate of bleeding-related complications was 29.9% and ranged from 7.5% to 47.4% for reproductive
organ and cardiac, respectively. Overall, incremental LOS associated with bleeding-related complications or
transfusions (unadjusted for covariates) was 6.0 days and ranged from 1.3 to 9.6 days for knee/hip replacement and
non-cardiac thoracic, respectively. The incremental cost per hospitalization associated with bleeding-related
complications and adjusted for covariates was highest for spinal surgery ($17,279) followed by vascular ($15,123),
solid organ ($13,210), non-cardiac thoracic ($13,473), cardiac ($10,279), general ($4,354), knee/hip replacement
($3,005), and reproductive organ ($2,805).
Conclusions: This study characterizes the increased hospital LOS and cost associated with bleeding-related
complications and/or transfusions occurring as a consequence of surgery, and supports implementation of blood-
conservation strategies.
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Bleeding can be a complication of surgery that may lead
to substantial morbidity and mortality. In cardiac surgery,
severe bleeding occurs in approximately 7% of cases [1]
and is associated with an increased risk of post-operative
mortality [2]. Mortality rates approaching 20% have been
observed in elective vascular patients with severe bleed-
ing complications [3]. In trauma patients, uncontrolled
bleeding is the cause of between 30%-40% of all trauma-
related deaths [4]. Bleeding complications may also occur
from percutaneous procedures that are not considered
surgical [5]. Approximately 7% of percutaneous coronary
interventions (PCI) performed emergently in patients
w i t ha c u t ec o r o n a r ys y n d r o m e result in major bleeding
[6]. As with procedures classified as surgical, severe
bleeding from PCI has also been linked to significant
increases in morbidity and mortality [7].
Blood transfusions, which can be planned/expected or
unexpected, and reoperations are used to control bleed-
ing and avert deaths. These procedures are often costly
and require large amounts of clinical and staff resources
[1]. Blood transfusions are not without considerable
risks including nosocomial infection [8,9], immunosup-
pression [10], transfusion-related acute lung injury [11],
and even death [12,13]. These complications may add
additional costs to the hospitalization and even post-
discharge medical care [1].
The purpose of this study was to estimate the
economic burden associated with bleeding-related compli-
cations and/or transfusions occurring as a consequence of
surgery in eight inpatient surgical cohorts, including car-
diac, vascular, non-cardiac thoracic, solid organ, general
surgery, knee/hip replacement, reproductive organ, and
spinal surgery. These procedures represent the majority of
all inpatient surgical procedures performed in the United
States (US)[14], and inpatient data on the costs of treating
patients with bleeding-related complications in these
procedure groups are limited.
Methods
Data Source
Data for this retrospective cohort study were obtained
from Premier’sP e r s p e c t i v e ™ Comparative Database
(PCD)[15]. The current study used PCD data containing
inpatient, clinical, drug utilization, and hospital billing
data from more than 600 hospitals throughout the US.
Premier collects data from participating hospitals in its
healthcare alliance. The Premier healthcare alliance was
formed for hospitals to share knowledge, improve
patient safety, and to reduce risks. Participation in the
Premier healthcare alliance is voluntary. The PCD is
comprised of hospital administrative data from the Uni-
ted States and, although the PCD excludes federally-
funded hospitals (e.g., Veterans Affairs), the hospitals
included are nationally representative based on bed size,
geographic location, and teaching hospital status [16].
Approximately 5 million new hospital discharges are
added to the database each year. According to the
Healthcare Utilization Project (HCUP) data, there were
39.5 million hospital discharges throughout the US in
2007 [17]. Therefore, the Premier data used at the time
of this analysis represented approximately 13% of all US
hospital discharges. All hospitals participating in the
healthcare alliance submit data on all patients, payors,
and providers as captured on the hospital billing record
t oP r e m i e r .T h ed a t ag ot h r o u g hq u a l i t ya s s u r a n c ea n d
validation checks and once the data have been validated
the information is added to the database. The PCD con-
tains a patient-level date-stamped log for all procedures,
medications, laboratory, and diagnostic services ren-
dered during the hospital stay. Data elements include
hospital and patient identifiers, primary and secondary
ICD-9-CM diagnosis and procedure codes, length of
hospital stay, admission type, and primary payer. Also
available are data elements for demographic and hospital
characteristics, including age, race, geographic location
of provider, hospital bed size, teaching hospital status,
and hospital location (urban or rural). Hospitals submit
demographic data including age and patient reported
race (White, Black, Hispanic, American Indian, Asian/
Pacific Islander, and Other). Data on hospital character-
istics including hospital bed size, teaching hospital status
(yes/no), and hospital location (urban/rural) are reported
by hospitals. The geographic location of the provider
(New England, Middle Atlantic, East North Central,
West North Central, South Atlantic, East South Central,
West South Central, Mountain, and Pacific) is based on
Centers for Medicare and Medicaid Services metropoli-
tan statistical area regions. Patient and provider infor-
mation contained within the PCD are de-identified
making it fully compliant with the Health Insurance
Portability and Accountability Act privacy regulations.
Institutional review board (IRB) approval for this study
was not required as dictated by Title 45 CFR (Code of
Federal Regulations) Part 46 of the United States under
the exemption that this research involved the study of
existing data and that the information was recorded in
such a manner that the subjects could not be identified,
directly or through identifiers linked to the subjects
[18]. Hence, IRB approval was not obtained.
Patient Population
All patients in the PCD undergoing an inpatient surgery
of interest (cardiac, vascular, non-cardiac thoracic, solid
organ, general, knee/hip replacement, reproductive
organ, and spinal surgery) from January 1, 2006 to
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of all ages were included in this study. Procedures
related to surgeries of interest were identified using the
International Classification of Diseases, Ninth Revision-
Clinical Modification (ICD-9-CM) procedure codes
(Table 1). For patients with multiple hospitalizations,
the most recent hospitalization (i.e., index) was selected
for analysis to maximize the pre-index study period
available for an assessment of baseline clinical and
demographic characteristics. Patients were excluded if
they were transferred from another hospital or an
unknown source to ensure that complete hospitalization
data were available for every patient. Patients were then
classified into study subgroups by procedure type (car-
diac, vascular, non-cardiac thoracic, solid organ, general
surgery, knee/hip replacement, reproductive organ, and
spinal surgery). A minority of patients (approximately
5%) was included in > 1 study subgroup because they
were operated on in surgical sites spanning multiple
surgical categories during the index hospitalization. For
example, patients who had an operation on the vessels
of their head and neck in addition to their heart valves
would have been included in the separate vascular and
cardiac cohort analyses, respectively.
Bleeding-related Complication and/or Blood Product
Transfusion status
Within each procedure cohort, patients were classified
into exposure groups according to whether a bleeding-
related complication and/or blood product transfusion
occurred during the hospital stay. Bleeding-related com-
plications and/or blood product transfusions were iden-
tified if the hospital record contained any of the
following codes: ICD-9-CM diagnosis codes for hemor-
rhages or hematomas complicating a procedure (998.11
and 998.12); ICD-9-CM procedure codes for interven-
tions, including return to the operating room to control
for bleeding (34.09, 21.0×, 42.33, 45.43, 44.44, 44.49,
54.19, 39.41, 60.94, 06.02, 28.7, 34.03, 54.12, 49.95, and
57.93); ICD-9-CM diagnosis codes for blood product
Table 1 ICD-9-CM Procedure Codes Used to Identify Surgical Subgroups
Type of Surgery ICD-9-CM Procedure Codes
Cardiac
Heart Valves 35.00-35.99
Heart Vessels 36.03, 36.10-36.2, 36.91-36.99
Other Operations on Heart and Pericardium 37.10-37.12, 37.31-37.54, 37.62-37.68
Miscellaneous 39.0, 39.61-39.64, 39.66, 33.6
Vascular
Incision, Excision, and Occlusion of Vessels 38.00-38.18, 38.30-38.49, 38.60-38.89
Other Operations on Vessels 39.21-39.41, 39.49
Non-cardiac Thoracic
Lung and Bronchus 32.01-32.21, 32.24, 32.25, 32.28-32.9
Other Operations on Lung and Bronchus 33.0-33.52, 33.91-33.99
Chest Wall, Pleura, Mediastinum, and Diaphragm 34.01-34.21, 34.24-34.27, 34.29-34.59, 34.72-34.89, 34.93-34.99
Esophagus 42.01, 42.09, 42.10-42.12, 42.19, 42.40-42.42, 42.51-42.59, 42.61-42.69, 42.7
General
Stomach 43.0, 43.19-43.3, 43.42-44.11, 44.15, 44.21, 44.29-44.43, 44.49-44.91, 44.95-44.99
Intestine 45.11, 45.13-45.15, 45.19, 45.26-45.41, 45.49-46.99
Gall Bladder 51.04, 51.13, 51.22-51.83, 51.89-51.94
Solid Organ
Pancreas 52.01-52.09, 52.12, 52.21-52.96, 52.99
Kidney 55.11, 55.12, 55.24, 55.31-55.91, 55.95-55.99
Liver 50.0, 50.12-50.99
Spleen 41.1, 41.2, 41.41-41.5, 41.93-41.99
Knee/Hip Replacement
Knee 81.54, 00.80-00.83
Hip 80.05, 81.51, 81.52, 81.53, 00.70-00.73, 00.85-00.87
Reproductive Organ
Male 60.0-63.71, 63.81-63.99, 64.11, 64.2-64.3, 64.42-64.45, 64.92, 64.93, 64.95-64.99
Female 65.01-66.11, 66.2-69.6, 69.91, 69.93-69.99, 70.12-70.14, 70.23-70.29, 70.32-71.11, 71.3-71.9
Spinal Surgery 03.2×, 03.4×, 03.5×, 03.6×, 84.6×, 84.8×, 81.0×, 81.3×, 81.62-81.64
ICD-9-CM = The International Classification of Diseases, Clinical Modification, Ninth Revision
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Page 3 of 13transfusions (V58.2, E879.8, E873.0, E934.7, and E876.0);
or ICD-9-CM procedure codes for blood product trans-
fusions (99.00-99.09).
Study Outcomes
The outcomes measured in this study included the total
length of stay (LOS) in days, the number of days spent
in an intensive care unit (ICU), and total hospital costs.
Total hospital costs were the actual treatment costs
incurred by the hospital and were the sum of the hospi-
tal’s direct and overhead costs. Direct costs represented
services that were used by the patient and included
items such as the costs of physicians employed directly
by the hospital, treatment costs, and food [19]. Direct
costs are recorded in the hospital accounting system as
they get itemized for each patient and represent the
costs of providing care from the hospital’s perspective.
Cost variables are not tied to reimbursement or pay-
ments from health insurers. Overhead costs were costs
associated with the overall functioning of the hospital
and included nursing, administrative, and management
staffing costs, as well as electricity and the depreciation
of medical equipment [19]. These costs are added to
each patient record in the hospital accounting system as
a standard cost according to the hospital department(s)
providing care. Costs accrued during the 2006 study
calendar year were standardized to 2007 $US using the
medical care component of the Consumer Price Index.
Data Analyses
The proportion of patients experiencing a particular
type of complication was assessed according to surgical
subgroup. Baseline demographic, clinical, and hospital
characteristics were evaluated according to bleeding-
related complication and/or blood product transfusion
status for all surgical subgroups combined. Pre-operative
use of substances that promote hemostasis was defined
as receipt of a hemostat in any of the hemostat classes
including oxidized regenerated cellulose, collagen,
gelatin, fibrin sealant, thrombin, flowables, combination
products, and adhesion prevention. Group comparisons
were made between patients with and without complica-
tions using 2-sided Pearson chi square and t-test
statistics for categorical and continuous measures,
respectively. Statistical significance was evaluated at
alpha = 0.05.
The total cost of hospitalization was analyzed for
patients with bleeding-related complications and/or
blood product transfusions versus those without a bleed-
ing-related complication or transfusion. Patients with
hospital costs exceeding $1,000,000 were excluded from
the analysis of costs. Multivariate ordinary least squares
regression models were created for each surgical popula-
tion to measure the impact of bleeding-related
complications and/or blood product transfusion events
on total hospital costs after controlling for important
baseline and clinical patient characteristics. As cost data
generally do not follow a normal distribution and are
often right-skewed, total costs were transformed to their
natural logs. Adjusted mean log costs were then retrans-
formed using Duan’s smearing estimate [20]. Baseline
parameters, clinical characteristics, and comorbid condi-
tions deemed to have an impact on total hospital costs
were considered for inclusion into multivariate models,
including bleeding-related complication and/or blood
product transfusion status, age, gender, race, geographic
region, hospital location, year of surgery, teaching hospi-
tal status, hospital bed size, surgical admission type
(urgent, elective, or emergency), any cause hospitaliza-
tion within 6 months prior to the index hospitalization,
surgery at multiple sites, and comorbid conditions as
independent variables. Comorbid conditions included
thrombocytopenia, myocardial infarction (MI), hyperten-
sion, non-MI coronary disease, diabetes, peripheral vas-
cular disease, obesity, chronic obstructive pulmonary
disease (COPD), renal disease, congestive heart failure,
cancer, deep vein thrombosis, and liver cirrhosis. All
comorbidities were modeled as separate covariates.
Statistical comparisons across groups were conducted
using a t-test evaluating the null hypothesis that the
parameter estimate for bleeding-related complications
and/or blood product transfusions is equal to 0. Statisti-
cal significance was evaluated at alpha = 0.05. The
incremental difference in adjusted mean hospital costs
between patients with a bleeding event and/or blood
product transfusion and those without these events was
assumed to be the hospital costs attributable to having a
bleeding event and/or blood product transfusion. Gener-
alized estimating equation (GEE) models with a Gamma
distribution and log link function were also used to
measure the impact of bleeding-related complications
and/or blood product transfusion events on total hospi-
tal costs while accounting for the effects related to the
clustering of patients receiving care from the same hos-
pitals. The same baseline parameters used for the ordin-
ary least squares regression models of total hospital
costs were included in GEE models.
Results
Table 2 displays the numbers of patients who developed
a bleeding-related complication and/or received a blood
product transfusion during the surgical hospitalization.
Results are displayed by complication type and surgical
subgroup. The percentage of patients with any type of
bleeding-related complication varied according to sub-
group (general: 27.5%; cardiac: 47.4%; solid organ:
28.5%; non-cardiac thoracic: 34.3%; vascular: 31.5%;
knee/hip replacement: 29.8%; reproductive organ: 7.5%;
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Page 4 of 13spine: 15.0%; and overall: 29.9%). The most common
type of event was blood product transfusion, which
occurred in 21.2% of all patients (cardiac: 45.8%; vascu-
lar: 29.1%; non-cardiac thoracic: 28.5%; solid organ:
26.8%; general: 25.0%; knee/hip replacement: 29.3%;
reproductive organ: 6.4%; and spine: 14.3%). The per-
centages of patients who had an intervention to control
for bleeding ranged from 0.0%-9.7% (cardiac: 3.1%; vas-
cular: 2.0%; non-cardiac thoracic: 9.7%; solid organ:
2.9%; general: 6.4%; knee/hip replacement: 0.0%; repro-
ductive organ: 0.5%; and spine: 0.3%). Overall, interven-
tions for bleeding control were relatively uncommon,
occurring in only 2.5% of all surgical patients.
Baseline demographic and clinical characteristics are
presented in Table 3 according to bleeding-related com-
plication and/or blood product transfusion status. All
differences in baseline demographic and clinical mea-
sures were highly significant across study groups due to
the large sample size. Patients less than 18 years of age
were included in this study and represented 2.5%, 1.2%,
4.6%, 3.7%, 2.6%, 0.03%, 0.9%, and 2.2% of patients in
the cardiac, vascular, non-cardiac thoracic, solid organ,
general, knee-hip replacement, reproductive organ, and
spinal surgery subgroups, respectively (data not shown).
It was possible for some patients to be operated on in
surgical sites spanning multiple surgical categories dur-
ing the index hospitalization. These patients accounted
for 15.5%, 15.1%, 20.2%, 41.8%, 11.3%, 1.0%, 3.2%, and
5.1% of patients in the cardiac, vascular, non-cardiac
thoracic, solid organ, general, knee-hip replacement,
reproductive organ, and spinal surgery subgroups,
respectively (data not shown).
The authors interpreted differences between groups to
be important for age, gender, primary payer, having a
prior surgery as well as comorbidities including diabetes,
COPD, and cancer. Patients who had a bleeding-related
complication were on average 8.9 years older compared
to patients without a complication (mean age 64.0 years
vs. 55.1, P< 0.001). There were also relevant differences
across study groups with respect to the patients’ primary
payer of medical care. There was a higher percentage of
patients experiencing a bleeding-related complication
and/or blood product transfusion who received Medicare
reimbursement versus patients without these events
(57.7% vs. 37.8%, P< 0.001). A higher percentage of male
patients had a bleeding-related complication versus those
without a complication (45.5% vs. 36.8%, P< 0.001).
Patients with bleeding-related complications and/or
b l o o dp r o d u c tt r a n s f u s i o n sw e r em o r el i k e l yt oh a v ed i a -
betes (46.2% vs. 26.1%, P< 0.001), COPD (25.2% vs.
18.7%, P< 0.001), and cancer (22.9% vs. 16.9%, P< 0.001)
compared to those without these events. We interpreted
statistically significant differences with respect to demo-
graphic characteristics such as race and geographic
region as unimportant. Additionally, differences in prior
hospitalization, pre-operative use of substances promot-
ing hemostasis, liver cirrhosis, and obesity were deemed
unimportant.
Table 4 reports the characteristics of the hospital in
which the surgery occurred. There were no relevant dif-
ferences in hospital size, hospital location (urban vs.
rural), or the proportion of patients treated in a teaching
hospital across study groups. However, differences were
statistically significant due to large sample sizes. The
authors interpreted the differences between study sub-
groups to be unimportant.
Data on hospitalization lengths of stay (data presented
in days and unadjusted for covariates) are presented in
Figure 1 by surgical cohort and complication status.
Patients with bleeding-related complications and/or
blood product transfusions experienced a longer LOS
compared to patients without bleeding-related complica-
tions and blood product transfusions (overall: 10.4 vs.
4.4 days; cardiac: 11.0 vs. 6.2 days; vascular: 15.2 vs. 5.9
days; solid organ: 13.4 vs. 5.3 days; non-cardiac thoracic:
18.7 vs. 9.1 days; general: 12.9 vs. 5.7 days; knee/hip
Table 2 Percentages of Patients with Specific Complication Events, by Surgical Subgroup
Complication Cardiac Vascular Non-cardiac
Thoracic
Solid
Organ
General Reproductive
Organ
Knee/Hip
Replacement
Spinal
Total number of patients 103,829 216,199 142,562 45,687 362,512 384,132 246,815 107,187
Bleeding event only, % 0.9% 1.9% 0.7% 1.0% 0.5% 0.8% 0.5% 0.5%
Re-operation to control bleeding only, % 0.4% 0.4% 4.7% 0.6% 1.9% 0.2% 0.0% 0.2%
Blood product transfusion only, % 40.9% 25.2% 22.7% 22.8% 19.9% 5.7% 28.6% 13.6%
Bleeding event and blood product transfusion, % 2.5% 2.4% 1.2% 1.8% 0.7% 0.5% 0.7% 0.6%
Bleeding event and re-operation to control
bleeding, %
0.3% 0.1% 0.4% 0.1% 0.1% 0.1% 0.0% 0.0%
Re-operation to control bleeding and blood
product transfusion, %
1.0% 1.1% 3.3% 1.5% 4.1% 0.1% 0.0% 0.1%
Bleeding event, re-operation to control bleeding
and blood product transfusion, %
1.4% 0.4% 1.3% 0.7% 0.3% 0.1% 0.0% 0.0%
Any bleeding-related consequences, % 47.4% 31.5% 34.3% 28.5% 27.5% 7.5% 29.8% 15.0%
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2.6 days; and spine: 7.8 vs. 3.3 days). Patients with
bleeding-related complications and/or blood product
transfusions in all surgical categories also spent more
days in an ICU versus patients without bleeding-related
complications and/or blood product transfusions (over-
all: 3.3 vs. 0.5 days; cardiac: 4.9 vs. 2.1 days; vascular: 6.0
vs. 1.2 days; solid organ: 4.4 vs. 0.6 days; non-cardiac
t h o r a c i c :8 . 9v s .2 . 5d a y s ;g e n e r a l :4 . 2v s .0 . 6d a y s ;k n e e /
hip replacement: 0.2 vs. 0.1 days; reproductive organ: 0.9
vs. 0.04 days; and spine: 1.7 vs. 0.3 days). Lengths of stay
differences were unadjusted for covariates.
Table 5 reports unadjusted total hospitalization costs
in 2007 US constant dollars. Total costs were higher
among patients with a bleeding-related complication
and/or blood transfusion versus those without a compli-
cation (cardiac: $43,125 vs. $26,073; vascular: $40,116
vs. $14,288; non-cardiac thoracic: $50,081 vs. $19,213;
solid organ: $41,667 vs. $16,480; general: $28,499 vs.
$11,937; knee/hip replacement: $18,973 vs. $14,966;
reproductive organ: $13,943 vs. $6,220; and spine:
$41,917 vs. $20,511).
Figure 2 presents mean total hospital costs by surgical
subgroup and complication status. Results were adjusted
for differences in baseline clinical, demographic, and
hospital characteristics between the bleeding-related
complication and/or blood product transfusion and no
bleeding-related complication and/or blood product
transfusion study groups using multivariate ordinary
least squares regression modelling techniques. In all sur-
gical subpopulations, the bleeding-related complication
and/or blood product transfusion groups had higher
total hospital costs versus those without a bleeding-
related complication and/or blood product transfusion
(P< 0.0001). There were large variations in the incre-
mental differences in mean total costs (bleeding-related
complication-no complication) for each of the surgical
subgroups (cardiac: $10,279; vascular: $15,123; non-car-
diac thoracic: $13,473; solid organ: $13,210; general:
$4,354; knee/hip replacement: $3,005; reproductive
organ: $2,805; and spine: $17,279).
Table 3 Baseline Demographics and Clinical
Characteristics, by Bleeding-related Complication and/or
Blood Product Transfusion Status
Characteristic Complication* No
Complication
P-value
Number of patients 351,065 1,175,208
Age, mean years (SD) 64.0 (17.9) 55.1 (18.7) < 0.001
Range 1-89 1-89
Male, N (%) 159,893
(45.5%)
432,211 (36.8%) < 0.001
Race, N (%)
White 231,146
(65.8%)
770,920 (65.6%) < 0.001
Black 46,288 (13.2%) 143,269 (12.2%)
Hispanic 12,842 (3.7%) 58,358 (5.0%)
Other 60,789 (17.3%) 202,661 (17.2%)
Geographic Region,
N (%)
Northeast 57,899 (16.5%) 163,160 (13.9%) < 0.001
South 170,133
(48.5%)
537,047 (45.7%)
Midwest 60,598 (17.3%) 259,391 (22.1%)
West 58,970 (16.8%) 204,439 (17.4%)
Unknown 3,465 (1.0%) 11,171 (1.0%)
Primary Payer, N (%)
Medicare 202,495
(57.7%)
443,685 (37.8%) < 0.001
Medicaid 24,477 (7.0%) 110,654 (9.4%)
Private 98,132 (28.0%) 524,710 (44.6%)
Uninsured 13,495 (3.8%) 45,219 (3.8%)
Other 12,466 (3.6%) 50,940 (4.3%)
Comorbidity, N (%)
Diabetes 162,097
(46.2%)
306,512 (26.1%) < 0.001
Obesity 41,646 (11.9%) 150,510 (12.8%) < 0.001
COPD 88,506 (25.2%) 219,635 (18.7%) < 0.001
Cancer 80,506 (22.9%) 198,206 (16.9%) < 0.001
Cirrhosis 11,034 (3.1%) 9,835 (0.8%) < 0.001
Prior Hospitalization,
N (%)
161,956
(46.1%)
486,348 (41.4%) < 0.001
Prior Surgery, N (%) 106,064
(30.2%)
293,533 (25.0%) < 0.001
Pre-operative use of
substances that
promote hemostasis,
N (%)
7,957 (2.3%) 21,338 (1.8%) < 0.001
N = number of patients, SD = standard deviation
*Bleeding complication and/or blood product transfusion
Table 4 Hospital Characteristics, by Bleeding-related
Complication and/or Blood Product Transfusion Status
Characteristic Complication* No Complication P-value
Number of patients 351,065 1,175,208
Hospital size–beds, N (%)
50-249 61,300 (17.5%) 219,235 (18.7%) < 0.001
250-749 250,774 (71.4%) 829,201 (70.6%)
750+ 38,991 (11.1%) 126,772 (10.8%)
Teaching hospital, N (%) 153,739 (43.8%) 505,674 (43.0%) < 0.001
Hospital location, N (%)
Urban 313,037 (89.2%) 1,043,060 (88.8%) < 0.001
Rural 34,563 (9.8%) 120,977 (10.3%)
Unknown 3,465 (1.0%) 11,171 (1.0%)
Hospital length of stay
Mean (SD) 10.4 (13.5) 4.5 (5.4) < 0.001
Median (Range) 6.0 (1-615) 3 (1-495)
N = number of patients, SD = standard deviation
*Bleeding complication and/or blood product transfusion
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patients with bleeding-related complications versus
those without bleeding-related complications, adjusted
for baseline, clinical characteristics and the effects
related to the clustering of patients receiving care from
the same hospitals using GEE models. Ordinary least
squares model results are also presented for comparison.
The ratio of average total costs estimated using GEE
models for patients with bleeding complications vs.
those without complications ranged from 1.31 to 1.93
for cardiac and vascular surgery, respectively. All aver-
age total cost ratios were statistically significant (P
<0.001). Cost ratios were similar to those observed
using OLS regression with the exception of the ratio for
general surgery (1.46 vs. 1.34 for GEE and OLS models,
respectively).
Discussion
We estimated the hospital costs associated with bleed-
ing-related complications in 8 surgical cohorts, including
cardiac, vascular, non-cardiac thoracic, solid organ, gen-
eral surgery, knee/hip replacement, reproductive organ,
and spinal surgery, using patient-level data from Pre-
mier’s PCD. Patients undergoing the surgical procedures
of interest during calendar years 2006 and 2007 were
identified using ICD-9-CM procedure codes. For each
surgical cohort, patients with bleeding-related complica-
tions and/or blood product transfusions and those with-
out these events were further delineated using a
combination of diagnosis and procedure codes. Mean
hospital costs were calculated for each study group after
adjusting for differences in baseline demographic and
clinical characteristics deemed to have an impact on
costs. The incremental difference in adjusted mean costs
between patients with a bleeding event and/or blood
product transfusion and those without these events was
assumed to be an estimate of the hospital costs attribu-
table to having a bleeding event and/or blood product
transfusion.
Results of our analyses indicate that bleeding events
and/or blood product transfusions were relatively com-
mon during the surgical hospitalization and varied
according to surgical cohort (general: 27.5%; cardiac:
47.4%; solid organ: 28.5%; non-cardiac thoracic: 34.3%;
vascular: 31.5%; knee/hip replacement: 29.8%; reproduc-
tive organ: 7.5%; and spinal surgery: 15.0%). Among the
types of events identified in this study, blood product
transfusions were the most common, occurring in
LOS LOS ICU
Days
LOS ICU
Days
LOS ICU
Days
LOS ICU
Days
LOS ICU
Days
LOS ICU
Days
Cardiac 
N=103,829
Vascular  
N=216,199
Non-cardiac
Thoracic  
N=142,562
Solid Organ 
N=45,687
General 
N=362,512
Knee/Hip 
Replacement 
N=246,815
Reproductive 
Organ
N=384,132
Spinal 
N=107,187
Figure 1 Mean Hospital LOS and ICU Days by Surgical Cohort and Complication Status.
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Page 7 of 13approximately 21.2% of the patient cohort. Interventions
for bleeding control, in contrast, were less common and
occurred in only 2.5% of patients.
In analyses of costs adjusted for disparities in baseline
and clinical characteristics, we observed large variations
in the incremental difference in mean total costs
between patients with a bleeding-related complication
and/or blood product transfusion and those without
these events for each surgical cohort. Patients with
bleeding-related complications and/or blood product
transfusions experienced longer hospital lengths of stay
and spent more time in the ICU compared to patients
without these events.
Studies investigating costs related to bleeding-related
complications reveal that they vary widely depending on
the surgical cohort. For example, hospital costs attribu-
table to bleeding in trauma patients are reported to be
much higher ($38,628) compared to patients undergoing
Table 5 Unadjusted Total Inpatient Costs (2007 $US), by Surgical Category and Bleeding-related Complication and/or
Blood Product Transfusion Status
Study Measure Complication* No Complication
Cardiac
Number of Patients 49,293 54,533
Mean (SD) $43,125 ($38,283) $26,073 ($22,083)
Median (Range) $33,468 ($24,921-
$47,466)
$22,512 ($14,620-$31,365)
Vascular
Number of Patients 68,211 147,980
Mean (SD) $40,116 ($49,461) $14,288 ($19,146)
Median (Range) $24,989 ($13,664-
$46,806)
$9,020 ($5,666-$15,952)
Non-cardiac thoracic
Number of Patients 48,854 93,699
Mean (SD) $50,081 ($57,926) $19,213 ($25,388)
Median (Range) $32,695 ($16,749-
$62,442)
$12,334 ($7,387-$21,127)
Solid organ
Number of Patients 12,988 32,699
Mean (SD) $41,667 ($49,699) $16,480 ($20,877)
Median (Range) $24,390 ($14,772-
$47,692)
$11,044 ($7,890-$17,125)
General
Number of Patients 99,812 262,695
Mean (SD) $28,499 ($42,485) $11,937 ($14,291)
Median (Range) $15,493 ($7,980-
$31,092)
$8,840 ($5,934-$13,325)
Knee/hip replacement
Number of Patients 73,795 173,020
Mean (SD) $18,973 ($12,247) $14,966 ($7,075)
Median (Range) $16,256 ($13,094-
$21,246)
$13,742 ($11,221-$17,209)
Reproductive organ
Number of Patients 28,951 355,180
Mean (SD) $13,943 ($19,905) $6,220 ($5,009)
Median (Range) $8,849 ($6,078-
$14,413)
$5,262 ($4,024-$7,090)
Spinal
Number of Patients 16,068 91,117
Mean (SD) $41,917 ($34,525) $20,511 ($16,114)
Median (Range) $32,813 ($22,393-
$49,884)
$16,557 ($10,541-$25,709)
SD = standard deviation
*Bleeding complication and/or blood product transfusion
Note: 15 patients were excluded from the economic analysis because their hospital costs exceeded $1,000,000
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Page 8 of 13more routine procedures such as PCI ($5,883) and knee
and hip surgery ($7,593) [21-23]. Our inpatient cost esti-
mates attributable to bleeding-related complications
and/or blood product transfusions ranged from $2,805-
$17,279 for reproductive and spinal surgery, respectively.
Considering that the surgical procedures examined in
this study were less complex compared to trauma
surgery, it makes sense that our estimates are lower
than what is previously reported for trauma patients.
This study is subject to several limitations. First, the
identification of patients who had a bleeding event and/
or blood product transfusion was based on an algorithm
utilizing a combination of ICD-9-CM procedure and
diagnosis codes as well as billing charges appearing on
($27,783 - $29,794)
($37,718 - $40,428)
($16,029 - $16,652)
($30,878 - $32,055)
($22,985 - $24,179)
($36,128 - $37,990)
($17,850 - $19,693)
($30,443 - $33,551)
($14,486 - $14,936)
($18,780 - $19,349)
($14,965 - $15,541)
($17,915 - $18,601)
($6,315 - $6,670)
($9,045 - $9,552)
($19,644 - $22,094)
($35,950 - $40,405)
Figure 2 Mean Total Adjusted
1 Hospital Costs (95% CIs) in 2007 $US by Surgical Cohort.
Table 6 Impact of Bleeding Complication Status on Total Hospital Costs: Comparison of GEE and OLS Models
Surgical Cohort GEE OLS
Model Estimate (CI)* P-value Model Estimate (CI)* P-value
Cardiac 1.31 (1.30, 1.32) < 0.001 1.36 (1.35, 1.36) < 0.001
Vascular 1.93 (1.93, 1.95) < 0.001 1.93 (1.92, 1.95) < 0.001
Non-cardiac thoracic 1.60 (1.58, 1.60) < 0.001 1.57 (1.55, 1.58) < 0.001
Solid organ 1.72 (1.68, 1.73) < 0.001 1.70 (1.68, 1.72) < 0.001
General 1.46 (1.46, 1.48) < 0.001 1.34 (1.34, 1.35) < 0.001
Knee/hip 1.22 (1.21, 1.22) < 0.001 1.20 (1.20, 1.21) < 0.001
Reproductive organ 1.49 (1.48, 1.51) < 0.001 1.43 (1.42, 1.43) < 0.001
Spinal 1.79 (1.77, 1.80) < 0.001 1.82 (1.80, 1.84) < 0.001
CI = confidence interval, GEE = generalized estimating equations, OLS = ordinary least squares
*Ratio of average total costs for patients with bleeding-related complications versus those without complications
Note: 15 patients were excluded from the economic analysis because their hospital costs exceeded $1,000,000.
GEE model estimated by gamma log link function with total costs as the dependent variable, adjusted for baseline clinical, demographic, hospital characteristics
and clustering on hospital.
OLS model with log total costs as the dependent variable, adjusted for baseline clinical, demographic, and hospital characteristics.
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Page 9 of 13the hospital record. These coding systems are primarily
used for administrative purposes in obtaining reimburse-
ment for the services provided by the hospital. There-
fore, we chose to incorporate both bleeding events as
well as blood product transfusions in our definition of
the study groups. This distinction is important because,
with certain surgical procedures, blood product transfu-
sions are routinely administered as part of the surgery
and not necessarily because the patient had unexpected
bleeding requiring transfusion. Thus, we felt we could
n o th a v er e l i a b l yd i s t i n g u i s h e do n et r a n s f u s i o nt y p e
from the other. Additionally, it was not possible to dif-
ferentiate between transfusions occurring as a conse-
quence of the surgery from transfusions that were the
result of an underlying or presenting condition such as
vascular trauma or ruptured aortic aneurysms if the
transfusion occurred on the same day of the surgery as
only data pertaining to the day of the transfusion were
available. Therefore, it is possible that some patients
within the bleeding-event and/or blood product transfu-
sion group had a transfusion that did not occur as a
consequence of the surgery and were misclassified. We
did not exclude patients with conditions such as vascu-
lar trauma or ruptured aortic aneurysms from this ana-
lysis in order to facilitate bleeding occurring as a
consequence of the surgery. Patients presenting with
aortic aneurysms probably would have undergone either
open aortic resection with replacement (38.44) or endo-
vascular repair (39.71). The proportion of vascular sur-
gery patients undergoing open aortic resection with
replacement was only 1.8% and patients undergoing
endovascular repair were not selected for this analysis.
Therefore, we do not expect the inclusion of patients
with ruptured aortic aneurysm and the possible misclas-
sification of the bleeding outcome to change results sig-
nificantly. With respect to vascular trauma, the
inclusion of trauma cases that likely had a transfusion as
a result of their presenting condition and not the surgi-
cal procedure probably introduced some misclassifica-
tion bias into this study. Since trauma patients have
much higher costs relative to patients without trauma,
the inclusion of these cases would have had the effect of
inflating our bleeding-related complication cost esti-
mates [21]. We suspect that this upward bias is probably
minimized by the fact that patients presenting with
trauma probably represented only a small percentage of
the total patients included in this study. A study from
the University of Michigan comparing outcomes
between trauma and general surgery patients reported
enrolling only 525 patients admitted to the Trauma ser-
vice in comparison to 54, 478 general surgery patients
during 2004 [21].
Second, patients were excluded from analyses if they
were transferred from another hospital or an unknown
source to ensure that complete hospitalization data were
available for every patient. We did not feel that we
could reliably identify and link multiple hospitalizations
for patients transferred to another hospital using the
administration codes in the database. As these trans-
ferred patients probably had higher costs relative to the
current sample of patients, the exclusion of these
patients likely had the effect of underestimating the
total inpatient episode of care. Furthermore, if more
patients with a bleeding-related complication were
transferred to other hospitals versus those without
bleeding-related complications, the incremental differ-
ence in costs between these groups may in fact be larger
than what is currently reported.
Third, pediatric patients < 18 years of age were
included in analyses. Although age was included as a
covariate in multivariate cost models, one could argue
that, because pediatric patients likely underwent differ-
ent procedures compared to adult patients, separate
analyses of these distinct patient groups is warranted.
Thus, multivariate cost models examining adult and
pediatric patients separately were constructed to provide
insight regarding the differences in costs between these
two distinct subpopulations. Among adults, patients
with bleeding-related complications had higher costs
relative to patients without complications (cardiac:
$38,686 vs. $28,914, vascular: $30,640 vs. $16,027, non-
cardiac thoracic: $36,150 vs. $23,494, solid organ:
$31,807 vs. $18,878, general surgery: $18,880 vs.
$14,427, knee/hip replacement: $18,248 vs. $15,247,
reproductive organ: $9,269 vs. $6,493, and spinal:
$37,978 vs. $20,847); results were similar to main ana-
lyses and statistically significant. Among the subset of
pediatric patients, those with bleeding-related complica-
tions had higher costs relative to patients without com-
plications (cardiac: $58,239 vs. $29,514, vascular:
$113,822 vs. $39,506, non-cardiac thoracic: $79,898 vs.
$35,680, solid organ: $61,122 vs. $28,742, general sur-
gery: $104,505 vs. $37,316, reproductive organ: $34,703
vs. $16,999, and spinal: $54,369 vs. $31,984). A multi-
variate model was not created for pediatric knee/hip
surgery patients because of the small sample size relative
to the number of parameters in the model. Overall,
costs in patients < 18 years of age were higher com-
pared to the adult population. The incremental differ-
ence in costs between patients with bleeding-related
consequences and those without bleeding-related conse-
quences was also higher in pediatric patients compared
to adults.
Fourth, our analyses of costs were adjusted for differ-
ences in baseline clinical and demographic characteris-
tics using multivariate ordinary least squares regression
with Duan’s smearing back retransformation. The
approach used for retransformation should be
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Page 10 of 13dependent upon the nature of the error term on the
transformed scale [24]. Since the distribution of the
error term is usually unknown, reliance on the assump-
tion of normality or homoskedasticity can lead to incon-
sistent estimates [24]. Therefore, we also examined the
sensitivity of results to retransformation using sub-
group-specific smearing factors as proposed by Manning
[25]. Using this alternate retransformation method, cost
estimates for patients with bleeding-related complica-
tions remained statistically significantly higher versus
those without complications. In fact, the incremental
differences in mean total costs (bleeding-related compli-
cation - no complication) for each of the surgical sub-
groups were higher compared to the main study results
(cardiac: $17,055, vascular: $25,795, non-cardiac thor-
acic: $30,963, solid organ: $25,153, general: $16,567,
knee/hip replacement: $4,009, reproductive organ:
$7,707, and spinal surgery: $21,326).
It should be noted that a small percentage of patients
(approximately 5%) were included in more than one
study subgroup because they were operated on in surgi-
cal sites spanning multiple surgical categories during the
index hospitalization. A sensitivity analysis excluding
these patients was conducted to examine the effect they
might have had on cost results. Results show that their
effect was minimal as the incremental difference in
mean total costs (bleeding-related complication - no
complication) were similar to the main analyses for each
of the surgical subgroups (cardiac: $10,391, vascular:
$14,639, non-cardiac thoracic: $12,366, solid organ:
$12,434, general: $3,974, knee/hip replacement: $3,148,
reproductive organ: $3,266, and spinal surgery: $17,448).
All baseline and clinical characteristics deemed to
have an impact on total hospital costs were included in
our models. Nevertheless, we could not control for cer-
tain covariates known to affect costs because this infor-
mation was not available in the PCD. These covariates
included sociodemographic parameters such as smoking
status and whether the patient was living alone.
Although we identified patients who were obese using
ICD-9-CM diagnosis codes (278.00-278.02), to the best
of our knowledge it is unknown to what extent these
codes can be used to accurately identify individuals who
are obese. Additionally, data on certain chronic comor-
bid conditions were likely underestimated. Comorbidity
data were only available if a patient was treated for the
condition during the index hospitalization or if a patient
was treated in a prior admission to a hospital within
Premier’s data capture network. Because data on outpa-
tient physician visits are not included in the PCD, for
some comorbidities including thrombocytopenia, MI,
hypertension, non-MI coronary disease, renal disease,
congestive heart failure, and deep vein thrombosis it
was impossible to determine whether the condition was
chronic and unrelated to the index surgical hospitaliza-
tion or occurred as an adverse event related to the sur-
gery or bleeding complication. Many patients also did
not have prior hospitalization data, therefore many
comorbidities were identified within the index surgical
hospitalization. As a result, the assumption of indepen-
dence between covariates in our multivariate analyses
may have been violated if, for example, certain condi-
tions such as MI or renal failure developed as a result
of the bleeding complication and were not actually
pre-existing conditions. As a result regression models
could have produced inaccurate estimates of regression
coefficients, variability, and P-values. Therefore, multi-
variate cost analyses were also run using only the con-
ditions that were deemed to be obvious chronic
conditions identifiable in the database. These condi-
tions included diabetes, obesity, COPD, cancer, and
cirrhosis. The incremental cost per hospitalization
associated with bleeding-related complications was
similar to the main study results ($15,931 for vascular,
$15,410 for solid organ, $14,653 for non-cardiac
thoracic, $11,715 for cardiac, $5,114 for general,
$3,119 for knee/hip replacement, $2,961 for reproduc-
tive organ, and $17,707 for spinal surgery) and the dif-
ference in costs among patients with bleeding-related
complications and those without complications was
statistically significant for every surgical cohort
(P< 0.001). We also did not control for conditions
such as coagulopathy, anemia, or the use of bone mar-
row suppressants. If a higher percentage of patients in
the bleeding complication group had these prior condi-
tions or procedures, our cost estimates related to
bleeding complications may have been overstated espe-
cially if a prior hospitalization for these conditions or
procedures was associated with higher costs during the
study index surgical hospitalization. Finally, informa-
tion relating to the severity of the comorbid condition
was not available. As severity could have an impact on
hospital costs, the inability to control for severity is
another limitation of our analysis.
Conclusions
These analyses offer insight into the magnitude of dif-
ferences in costs between patients with and without
bleeding-related complications and/or blood product
transfusions among hospital-based procedures in 7 spe-
cialties. The optimal management of bleeding is an
important goal, as these complications are associated
with increased morbidity and mortality in a variety of
different surgical populations [2-4,7]. Given the high
costs associated with managing patients with bleeding-
related complications and/or blood product transfu-
sions, additional comprehensive approaches should be
evaluated or developed to optimize intra-operative
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Page 11 of 13bleeding management, including product and technique
strategies.
Key Messages
￿ In every surgical cohort examined, patients with
bleeding-related complications and/or blood product
transfusions had longer lengths of stays and higher
total hospital costs.
￿ There were large variations in the incremental dif-
ferences in total hospital costs between bleeding-
related complication and no complication cohorts
for each of the surgical subgroups (cardiac: $10,279;
vascular: $15,123; non-cardiac thoracic: $13,473;
solid organ: $13,210; general: $4,354; knee/hip repla-
cement: $3,005; reproductive organ: $2,805; and
spine: $17,279).
￿ Patients with bleeding-related complications and/or
blood product transfusions spent, on average,
approximately 2.7 more days in an ICU compared to
patients without bleeding-related complications and
blood product transfusions (overall: 3.3 vs. 0.5 days).
￿ Given the high costs associated with managing
patients with bleeding-related complications and/or
blood product transfusions, additional comprehen-
sive approaches should be evaluated or developed to
optimize intra-operative bleeding management,
including product and technique strategies.
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